23 July 2015
EMA/CHMP/448343/2015
Committee for Medicinal Products for Human Use (CHMP)

Assessment report

Pemtrexed Lilly

International non-proprietary name: pemetrexed

Procedure No. EMEA/H/C/004114/0000

Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.
# Table of contents

1. **Background information on the procedure** .............................................. 5  
   1.1. Submission of the dossier ..................................................................................... 5  
   1.2. Steps taken for the assessment of the product ......................................................... 6  

2. **Scientific discussion** ................................................................................ 7  
   2.1. Introduction ........................................................................................................ 7  
   2.2. The development programme/Compliance with CHMP Guidance/Scientific Advice ...... 8  
   2.3. General comments on compliance with GMP, GLP, GCP ................................................ 8  
   2.4. Quality aspects .................................................................................................... 8  
      2.4.1. Introduction...................................................................................................... 8  
      2.4.2. Active substance ............................................................................................... 8  
      2.4.3. Finished medicinal product ............................................................................... 11  
      2.4.4. Discussion on chemical, and pharmaceutical aspects ........................................... 13  
      2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects .................. 14  
      2.4.6. Recommendation(s) for future quality development ............................................. 14  
   2.5. Non-clinical aspects ............................................................................................ 14  
      2.5.1. Introduction..................................................................................................... 14  
      2.5.2. Ecotoxicity/environmental risk assessment ........................................................... 14  
      2.5.3. Discussion and conclusion on non-clinical aspects ............................................... 14  
   2.6. Clinical aspects .................................................................................................. 15  
      2.6.1. Introduction.................................................................................................... 15  
      2.6.2. Pharmacokinetics ............................................................................................ 15  
      2.6.3. Pharmacodynamics .......................................................................................... 15  
      2.6.4. Post marketing experience ............................................................................... 15  
      2.6.5. Discussion on clinical aspects ............................................................................ 15  
      2.6.6. Conclusion on clinical aspects ........................................................................... 15  
   2.7. Pharmacovigilance ............................................................................................. 16  
   2.8. Risk management plan ....................................................................................... 16  
   2.9. PSUR submission ............................................................................................... 17  
   2.10. Product information .......................................................................................... 17  
      2.10.1. User consultation ........................................................................................... 17  

3. **Benefit-risk balance** .............................................................................. 18  

4. **Recommendation** .................................................................................. 18
List of abbreviations

API    Active pharmaceutical ingredient
ASMF   Active Substance Master File
BSA    Body Surface Area
CHMP   Committee for Human Medicinal Products
DMF    Drug master File
EMA    European Medicines Agency
GC     Gas Chromatography
GI     Gastrointestinal
HPLC   High performance liquid chromatography
ICH    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
(FT-)IR Fourier transformed Infrared spectroscopy
KF     Karl Fischer
LLDPE  Linear Low density polyethylene
LoD    Limit of Detection
LoQ    Limit of Quantification
MAA    Marketing authorisation application
MS     Mass Spectrometry
NfG    Note for Guidance
NIR    Near Infrared spectroscopy
NMR    Nuclear Magnetic Resonance
NMT    Not more than
Ph. Eur. European pharmacopoeia
PRAC   Pharmacovigilance risk assessment committee
RH     Relative Humidity
RMP    Risk Management Plan
SJS    Stevens-Johnson syndrome
SmPC   Summary of Product Characteristics
TEN    Toxic epidermal necrolysis
TLC  Thin Layer chromatography
XR(P)D  X-Ray (Powder) Diffraction
1. Background information on the procedure

1.1. Submission of the dossier

The applicant Eli Lilly Netherlands submitted on 3 December 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Pemetrexed Lilly, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004– ‘Generic of a Centrally authorised product’. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 20 November 2014.

The application concerns a generic medicinal product as defined in Article 10(2)(b) of Directive 2001/83/EC and refers to a reference product for which a Marketing Authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Article 8(3) of Directive 2001/83/EC.

The applicant applied for the following indications:

Malignant pleural mesothelioma

Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer

Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

The legal basis for this application refers to:

Generic application (Article 10(1) of Directive No 2001/83/EC).

The application submitted is composed of administrative information and complete quality data. There is no requirement for bioequivalence testing according to (cf.CPMP/QWP/EWP/1401/98 Rev. 1).

Information on paediatric requirements

Not applicable

The chosen reference product is:

- Medicinal product which is or has been authorised in accordance with Community provisions in accordance with Community provisions in force for not less than 6/10 years in the EEA:
- Product name, strength, pharmaceutical form: Alimta, 100 mg and 500 mg, powder for concentrate for solution for infusion
Marketing authorisation holder: Eli Lilly Nederland B.V.
Date of authorisation: 22-09-2004
Marketing authorisation granted by:
  – Community
  • Community Marketing authorisation number: EU/1/04/290/001,002

Medicinal product authorised in the Community/Members State where the application is made or European reference medicinal product:

• Product name, strength, pharmaceutical form: Alimta 100 mg, 500 mg, powder for concentrate for solution for infusion
• Marketing authorisation holder: Eli Lilly Nederland B.V.
• Date of authorisation: 22-09-2004
• Marketing authorisation granted by:
  – Community
  • Community Marketing authorisation number: EU/1/04/290/001-002

**Licensing status**

The product was not licensed in any country at the time of submission of the application.

**1.2. Steps taken for the assessment of the product**

The Rapporteur appointed by the CHMP:

Rapporteur: Alar Irs

• The application was received by the EMA on 3 December 2014.
• The procedure started on 24 December 2014.
• The Rapporteur's first Assessment Report was circulated to all CHMP members on 13 March 2015.
• PRAC RMP Advice and assessment overview, adopted by PRAC on 10 April 2015.
• During the meeting on 23 April 2015, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 23 April 2015.
• The applicant submitted the responses to the CHMP consolidated List of Questions on 22 May 2015.
• The Rapporteur circulated the Assessment Report on the applicant’s responses to the List of Questions to all CHMP members on 26 June 2015.
• During the meeting on 23 July 2015, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Pemetrexed Lilly.
2. Scientific discussion

2.1. Introduction

This application concerns a generic version of pemetrexed powder for concentrate for solution for infusion. Pemetrexed Lilly 100 mg or 500 mg Powder for Concentrate for Solution for Infusion is the same product (same qualitative and quantitative composition, same pharmaceutical form, same Marketing Authorisation Holder, Eli Lilly Nederland B.V.) as the centrally approved reference medicinal product Alimta (EU/1/04/290/001-002). Each vial contains 100 mg or 500 mg of pemetrexed (as pemetrexed disodium). After reconstitution, each vial contains 25 mg/ml of pemetrexed.

The claimed indications for Pemetrexed Lilly are:

Malignant pleural mesothelioma

Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer

Pemetrexed Lilly is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

As monotherapy or in combination with cisplatin the recommended dose of Pemetrexed Lilly is 500 mg/m² of body surface area (BSA) administered as an intravenous infusion over 10 minutes on the first day of each 21-day cycle.

Pemetrexed Lilly must be reconstituted and further diluted prior to use. After reconstitution, each strength of the proposed product contains 25 mg/ml of pemetrexed.

About the product

Pemetrexed is a multi-targeted anti-cancer antifolate agent that exerts its action by disrupting crucial folate-dependent metabolic processes essential for cell replication.

Mode of action

In vitro studies have shown that pemetrexed behaves as a multitargeted antifolate by inhibiting thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are key folate-dependent enzymes for the de novo biosynthesis of thymidine and purine nucleotides. Pemetrexed is transported into cells by both the reduced folate carrier and membrane folate binding protein transport systems. Once in the cell, pemetrexed is rapidly and efficiently converted to polyglutamate forms by the enzyme folylpolyglutamate synthetase.

The polyglutamate forms are retained in cells and are even more potent inhibitors of TS and GARFT.
Polyglutamation is a time- and concentration-dependent process that occurs in tumour cells and, to a lesser extent, in normal tissues. Polyglutamated metabolites have an increased intracellular half-life resulting in prolonged drug action in malignant cells.

2.2. The development programme/Compliance with CHMP Guidance/Scientific Advice

N/A

2.3. General comments on compliance with GMP, GLP, GCP

An inspection of Eli Lilly & Co., Lilly Corporate Center Indianapolis in accordance with Article 19(3) of Regulation (EC) 726/2004 has been requested. No specific quality issues have been identified that specifically demand for an inspection.

2.4. Quality aspects

2.4.1. Introduction

The finished product is presented as a powder for concentrate for solution for infusion containing 100 mg/vial or 500 mg/vial of pemetrexed (as disodium salt) as active substance.

Other ingredients are: mannitol (E421) hydrochloric acid and sodium hydroxide, as described in section 6.1 of the SmPC.

Pemetrexed Lilly powder for concentrate for solution for infusion is available in Type I clear glass vial with bromobutyl rubber stopper and an aluminium seal with a polypropylene flip top, as described in section 6.5 of the SmPC.

The proposed generic medicinal product Pemetrexed Lilly and the centrally approved reference medicinal Alimta (EU/1/04/290/001-002) are the same product (same qualitative and quantitative composition, same pharmaceutical form, same Marketing Authorisation Holder).

2.4.2. Active substance

General information

The chemical name of the active substance pemetrexed disodium (heptahydrate) is L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-disodium salt, corresponding to the molecular formula C_{20}H_{19}N_{5}Na_{2}O_{6}•7H_{2}O and has a relative molecular mass 597.49 g/mol. The active substance has the following structure:
The structure of the active substance has been confirmed by quantitative elemental analysis, mass spectra, $^1$H- and $^{13}$C-NMR, FT-IR data and X-ray diffraction all of which support the chemical structure.

It appears as a white to almost-white, amorphous, non-hygroscopic crystalline powder. It is freely soluble in water 0.01N HCl, Formate Buffer, pH 4.0, 0.1N NaOH, very slightly soluble in 0.1N HCl and ethanol, and soluble in methanol.

Pemetrexed disodium contains a single chiral centre at carbon-4. It is synthesized from L-glutamic acid; therefore, the chiral carbon is in the L-configuration (S-configuration) which has been confirmed by single crystal x-ray diffraction analysis. All clinical trials and toxicology studies have been conducted with batches of pemetrexed disodium that contained less than 0.5% of the D-isomer. Enantiomeric purity is tested in the active substance by specific chiral HPLC as per Ph. Eur. monograph.

Pemetrexed disodium is known to exist in two crystalline hydrate forms, a 2.5 mole hydrate (hemipentahydrate) form and a 7 mole hydrate (heptahydrate) form. Pemetrexed disodium heptahydrate form is manufactured and controlled by water content determined by KF titration. The heptahydrate form has a Ph. Eur. monograph. Stability studies have demonstrated that pemetrexed disodium is stable and can be stored as the heptahydrate form.

The quality documentation regarding the active substance is identical with the authorised dossier for Alimta.

**Manufacture, characterisation and process controls**

Pemetrexed disodium heptahydrate is synthesized in a seven-step process split between two manufacturing sites from well-defined starting materials with acceptable specifications. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented. Comparative data using the starting materials from all different suppliers were provided with no significant effect on the quality of the final active substance.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised.

Initial clinical trial and acute toxicology lots of pemetrexed disodium were prepared as the 2.5 hydrate (hemipentahydrate). The change in crystal form was made to improve quality characteristics of the active substance. The initial hemipentahydrate form is not stable to water content and readily changes mass depending on ambient humidity.

The active substance is packaged in a Linear Low-Density Polyethylene (LLDPE) liner, with antistatic and antiblock additives placed inside a secondary laminated foil liner and stored inside an appropriate container such as a fibre drum, corrugated container, polyethylene drum, or metal drum for shipping and handling. The primary packaging material complies with the relevant EC directives.
**Specification**

The active substance specification includes tests for: appearance (visual), \( \text{pH} \) (Ph. Eur.), water (Ph. Eur.), colour and clarity of solution (Ph. Eur.), identity (Ph. Eur.), sodium (Ph. Eur.), assay (Ph. Eur.), impurities (Ph. Eur.), D-isomer (Ph. Eur.), residual solvents (GC), water content (titration), heavy metals (Ph. Eur.), microbial limits (Ph. Eur.) and bacterial endotoxins (Ph. Eur.). The active substance meets the requirements of the current edition of the Ph. Eur. monograph for pemetrexed disodium heptahydrate. Stricter acceptance criteria for microbiological quality than those requested in Ph. Eur. for non-sterile substances for pharmaceutical use are applied. The analytical methods used have been adequately described and (non-compendial methods) appropriately validated in accordance with the ICH guidelines. Satisfactory information on the reference standards has been provided.

Batch analysis results for five pemetrexed disodium heptahydrate batches manufactured at the proposed site at full-scale using the commercial process were presented. The results indicate compliance with Ph. Eur. monograph.

**Stability**

Stability data on five production scale batches of active substance manufactured at the commercial sites and stored in packaging intended for marketing for up to 36 months at 25 °C / 60% RH (long-term condition), for up to six months at 40 °C / 75% RH (accelerated condition), and for up to 36 months at 5°C (backup condition for long-term storage) were provided. Stability studies were conducted according to the ICH guidelines. The following parameters were tested: package characteristics, description, assay, related substances (total and individuals), water, colour and clarity. The analytical methods used were the same as for release and were stability indicating. No significant change in any of the tested parameters was observed over the time-points evaluated at long-term or accelerated conditions.

Supporting stability data on three production scale batches of active substance manufactured during development at a different site and stored in packaging intended for marketing for up to 36 months at 25 °C / 60% RH (long-term condition), for up to six months at 40 °C / 75% RH (accelerated condition), and for up to 36 months at 5°C were also provided. Stability studies were conducted according to the ICH guidelines. Samples were tested: package characteristics, description, assay, related substances (total and largest individual), D-isomer and water. The analytical methods used were the same as for release and were stability indicating. No significant change in any of the tested parameters was observed over the time-points evaluated at long-term or accelerated conditions.

The first three production batches manufactured at the proposed manufacturing site, at the commercial scale have been placed on stability studies.

Stress studies were performed on one commercial scale batch in solid state and unprotected (open-dish), exposed to heat (60 °C at uncontrolled humidity, 6 months), humidity (25 °C / 90% RH, 6 months), and heat and humidity (40 °C / 75% RH, 6 months). Pemetrexed disodium showed no significant change in assay, related substances, D-isomer, or water content over 6 months for the 25 °C / 90% RH and 40 °C / 75% RH conditions. As anticipated, increased impurity levels were observed at the 60°C condition over 6 months.

A photostability study was conducted as per ICH Q1B requirements on one commercial scale batch. The photostability study did not show a significant change in assay, D-isomer, or related substances, or any other unexpected change.
In conclusion, the proposed re-test period of 3 years with no specific storage restrictions when the active substance is stored in the proposed packaging is adequately supported by the stability data provided and is acceptable.

2.4.3. Finished medicinal product

Description of the product and pharmaceutical development

The proposed generic medicinal product Pemetrexed Lilly and the centrally approved reference medicinal Alimta (EU/1/04/290/001-002) share the same qualitative and quantitative composition, same pharmaceutical form, same Marketing Authorisation Holder, Eli Lilly Nederland B.V. (The Netherlands). The quality documentation submitted for the current application is identical with the authorised dossier for Alimta. Since the generic and reference product are the same, there are no differences with regards to quality.

Pemetrexed Lilly powder for concentrate for solution for infusion is presented in two strengths: 100 mg/vial and 500 mg/vial. The product is a sterile lyophilised powder that must be reconstituted and then diluted with a suitable intravenous solution prior to administration. Each 100 mg vial and 500 mg vial are reconstituted respectively with 4.2 ml or 20 ml of commercially available 0.9% Sodium Chloride Injection, without preservatives. The reconstituted solution contains 25 mg/ml of pemetrexed. The required amount of the reconstituted pemetrexed solution is further diluted to 100 ml in 0.9% Sodium Chloride Injection prior to intravenous infusion.

The hemipentahydrate form was used in early development formulations but there were handling issues observed because it is hygroscopic. The heptahydrate form was determined to be more stable with respect to relative humidity and was therefore selected. Since the manufacture of pemetrexed powder for concentrate for solution for infusion involves dissolution of the active substance, the solubility of the drug substance is an important physicochemical property. Considering that the active substance is sensitive to degradation by hydrolysis and oxidation (presence of oxygen) pH range was selected to minimise hydrolysis. Oxidation is controlled in the commercial formulation by minimising exposure to oxygen using a nitrogen overlay.

In addition the effect of headspace oxygen was evaluated; it was demonstrated that the product stability is acceptable when the headspace oxygen is controlled within specific limits. The impact of light on the stability of the drug product solution during manufacturing was studied and it was concluded that no additional protection from light is required during manufacturing.

The excipients used in the formulation of the product are the same as those used in the reference product Alimta. Both the 100 mg/vial and the 500 mg/vial are filled from a common 25 mg/ml bulk solution.

Formulation development efforts were initially directed toward developing a terminally sterilised solution formulation. This was changed to a lyophilised terminally sterilised formulation because of stability issues with the solution formulation. Potential terminal sterilisation was evaluated using the "Decision Tree for Sterilisation Choices for non-Aqueous Liquid, Semi-Solid or Dry Powder Products" in regulatory guidance CPMP/QWP/054/98. Sterilisation by dry heat or by ionizing radiation (e-beam) was shown to be not acceptable for this lyophilised product. Therefore, the product is sterilised by filtration of the manufactured solution using a validated process followed by aseptic processing. Bioburden levels in the active substance are controlled and monitored. The lyophilisation cycle of has been optimised during development. The XRPD data of the commercial cycle and development cycle show that solid-state characteristics are similar, with amorphous pemetrexed and crystalline mannitol.
A microbial challenge study was performed on pemetrexed manufactured solution and demonstrated that the solution is neither growth promoting or inhibiting up to 96 hours. Based on the results a processing time limit has been established from the start of solution manufacture until the end of pre-filtration.

The compatibility studies were designed to assure that the drug product is compatible with the diluent and the container closure system. Based on these studies, compatibility has been demonstrated when the product is reconstituted and diluted with the media and administered with the materials as described in the SmPC (section 6.6). However Pemetrexed Lilly powder for concentrate for solution for infusion is not compatible with Ringer's Injection or Lactated Ringer's Injection due to the calcium chloride component of the Ringer's solutions.

The product packaging components for the 100 mg/vial and 500 mg/vial configurations are 10ml and 50 ml type I clear glass vial with bromobutyl rubber stopper and an aluminium seal with a polypropylene flip top.

The glass containers as well as rubber stoppers comply with the requirements of the relevant monographs of Ph. Eur. Compatibility of the stopper to the reconstituted solution has been tested. The results for the inverted vials indicate the stopper has no impact on the reconstituted product stability. The container closure system has been demonstrated to maintain integrity using a microbial ingress method.

**Manufacture of the product and process controls**

The product is manufactured in six main steps: preparation of solution, pre-filtration, sterile filtration-filling-stoppering, lyophilisation, sealing, and secondary packaging-labelling. The critical steps have been identified and adequate in-process controls, including solution pH and bioburden, tank purging with nitrogen, temperature of solution, filter integrity and processing times, are in place for this type of manufacturing process.

In accordance with Annex II to the guideline on process validation the aseptic manufacturing process by sterile filtration in combination with a lyophilisation process is considered a non-standard manufacturing process. Process validation has been performed on three consecutive production scale batches for both 100 ml and 500 ml vial. It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

**Product specification**

The finished product release and shelf life specifications include appropriate tests and limits for this kind of dosage form including description (visual), reconstitution time, clarity, colour and pH of solution (Ph. Eur.), identification (TLC, HPLC), uniformity of dosage units (Ph. Eur.), assay (HPLC), impurities (HPLC), particulate matter (Ph. Eur.), water content (KF or NIR), headspace oxygen (electrochemical), sterility (Ph. Eur.) and bacterial endotoxins (Ph. Eur.). Endotoxins are not tested at the end of shelf life, because it is not considered a stability-indicating parameter. The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards of active substance and impurities has been presented.

Batch analysis results are provided for seven production scale batches of 100 mg/vial presentation and eight production scale batches of the 500 mg/vial strength manufactured at the proposed site. All results comply with the proposed specifications. The presented results confirm the consistency of the manufacturing process and its ability to manufacture to the intended product specification.
**Stability of the product**

Stability data on four batches of the 100 mg/vial strength, four batches of the 500 mg/vial strength, all manufactured at production scale and stored for up to 36 months under long term conditions (25 °C / 60% RH), for up to 36 months under intermediate conditions (30 °C / 75% RH) were provided. There were some deviations from the ICH guidelines in that product has not been studied under accelerated conditions (40 °C / 75% RH) and also with regards to the frequency of testing. The stability study results at the accelerated conditions are available for Alimta. Taking into account the fact that the proposed generic medicinal product Pemetrexed Lilly 100mg and 500mg and the centrally approved reference medicinal product Alimta 100 mg and 500 mg are the same product, this was considered acceptable. Also the deviation in the frequency of testing was accepted on the basis of the well established stability profile of the product (the proposed MAH has approximately 11 years of experience with the product).

Samples were tested for appearance of the powder, particulate matter of the reconstituted solution, colour and clarity of the reconstituted solution, water content, reconstitution time, pH of the reconstituted solution, assay, purity tests and sterility with the methods used for release. The stability data for both strengths is within the shelf-life specifications and there are no trends present in the data generated for both storage conditions.

In-use stability studies on the reconstituted product with sodium chloride 0.9% were provided. Compatibility of the stopper to the reconstituted solution has been tested during development studies when vials were stored upright and inverted positions. The results for the inverted vials were acceptable. The proposed in-use storage statement of the SmPC (section 6.3) “Chemical and physical in-use stability after reconstitution and further dilution in 0.9 % Sodium Chloride solution has been demonstrated for 24 hours at 2 °C to 8 ºC” is acceptable.

Photostability studies in accordance with the ICH conditions were conducted on the finished product. Photostability studies were also conducted on product reconstituted with 0.9% Sodium Chloride Injection (preservative free), and the product reconstituted and further diluted in IV bags with 0.9% Sodium Chloride Injection (preservative free). Based on the results protection from light is not required under the typical in-use conditions.

The proposed shelf life and storage condition are considered justified as they are the same as currently approved for Alimta.

Based on the data and justification provided the proposed shelf-life of 36 months and storage conditions “This medicinal product does not require any special storage conditions” as stated in the SmPC (section 6.3 and 6.4) are accepted.

**Adventitious agents**

No excipients of human or animal origin are used.

**2.4.4. Discussion on chemical, and pharmaceutical aspects**

The proposed generic medicinal product Pemetrexed Lilly and the centrally approved reference medicinal Alimta (EU/1/04/290/001-002) share the same qualitative and quantitative composition, same pharmaceutical form, same Marketing Authorisation Holder, Eli Lilly Nederland B.V. (The Netherlands). The quality documentation submitted for the current application is identical with the authorised dossier for Alimta. Since the generic and reference product are the same, there are no differences with regards to quality.
Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

2.4.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

2.4.6. Recommendation(s) for future quality development

Not applicable.

2.5. Non-clinical aspects

2.5.1. Introduction

A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. The non-clinical aspects of the SmPC are in line with the SmPC of the reference product. The impurity profile has been discussed and was considered acceptable.

Therefore, the CHMP agreed that no further non-clinical studies are required.

2.5.2. Ecotoxicity/environmental risk assessment

No Environmental Risk Assessment was submitted. This was justified by the applicant as the introduction of Pemetrexed Lilly manufactured by Eli Lilly is considered unlikely to result in any significant increase in the combined sales volumes for all pemetrexed containing products and the exposure of the environment to the active substance. Thus, the ERA is expected to be similar and not increased.

2.5.3. Discussion and conclusion on non-clinical aspects

Pharmacodynamic, pharmacokinetic and toxicological properties of pemetrexed are well known. No non-clinical data are submitted with this application. Published literature has been reviewed and is considered of suitable quality.

In line with the Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00), the justification for not providing new ERA studies is acceptable.
2.6. **Clinical aspects**

2.6.1. **Introduction**

This is an application for powder for concentrate for solution for infusion containing pemetrexed.

The applicant provided a clinical overview outlining the pharmacokinetics and pharmacodynamics as well as efficacy and safety of pemetrexed based on published literature. The SmPC is in line with the SmPC of the reference product.

No CHMP scientific advice pertinent to the clinical development was given for this medicinal product.

**Exemption**

According to the Guideline on the Investigation of bioequivalence (CPMP/EWP/QWP/1401/98), bioequivalence studies are generally not required if the product is to be administered as an aqueous intravenous solution containing the same active drug substance in the same concentration as the currently authorised product. Pemetrexed Lilly is to be administered as an intravenous aqueous solution and contains the same active drug substance at the same concentration as the reference product (25 mg/mL) therefore, no bioequivalence studies are required.

2.6.2. **Pharmacokinetics**

No new pharmacokinetic studies were presented and no such studies are required for this application.

2.6.3. **Pharmacodynamics**

No new pharmacodynamic studies were presented and no such studies are required for this application.

2.6.4. **Post marketing experience**

No post-marketing data are available. The medicinal product has not been marketed in any country.

2.6.5. **Discussion on clinical aspects**

There are no concerns with Pemetrexed Lilly from a clinical efficacy point of view.

No new studies have been conducted and none are required under the provisions of the Note for Guidance on the investigation of Bioequivalence and Bioavailability (CPMP/EWP/QWP/1401/98/Rev. 1): "Bioequivalence studies are generally not required if the test product is to be administered as an aqueous intravenous solution containing the same active substance as the currently approved product”.

2.6.6. **Conclusion on clinical aspects**

The CHMP considers that there are no objections to approval of Pemetrexed Lilly powder for concentrate for solution for infusion from a clinical point of view.
2.7. Pharmacovigilance

Detailed description of the pharmacovigilance system

The CHMP considered that the Pharmacovigilance system as described by the applicant fulfils the legislative requirements.

2.8. Risk management plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 1.0 could be acceptable if the applicant implements the changes to the RMP as described in the PRAC advice.

The CHMP endorsed this advice without changes.

The applicant implemented the changes in the RMP as requested by PRAC and/or CHMP.

The CHMP endorsed the Risk Management Plan version 1.0 with the following content:

Safety concerns

<table>
<thead>
<tr>
<th>Summary of safety concerns</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Important identified risks</td>
<td>Non-compliance with folic acid and vitamin B12 regimens manifested mainly as haematological and gastrointestinal (GI) toxicities.</td>
</tr>
<tr>
<td></td>
<td>Serious renal events</td>
</tr>
<tr>
<td></td>
<td>Gastrointestinal disorders</td>
</tr>
<tr>
<td></td>
<td>Interstitial pneumonitis</td>
</tr>
<tr>
<td></td>
<td>Radiation pneumonitis</td>
</tr>
<tr>
<td></td>
<td>Radiation recall</td>
</tr>
<tr>
<td></td>
<td>Sepsis</td>
</tr>
<tr>
<td></td>
<td>Bullous skin reaction including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)</td>
</tr>
<tr>
<td>Important potential risks</td>
<td>Cardiovascular events</td>
</tr>
<tr>
<td></td>
<td>Peripheral vascular disorders</td>
</tr>
<tr>
<td></td>
<td>Hearing loss/hypoacusis</td>
</tr>
<tr>
<td>Missing information</td>
<td>None</td>
</tr>
</tbody>
</table>
**Pharmacovigilance plan**

Routine pharmacovigilance is sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV is sufficient to monitor the effectiveness of the risk minimisation measures.

**Risk minimisation measures**

<table>
<thead>
<tr>
<th>Safety concern</th>
<th>Routine risk minimisation measures</th>
<th>Additional risk minimisation measures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncompliance with folic acid and vitamin B12 regimens manifested mainly as haematological and gastrointestinal (GI) toxicities</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>GI disorders</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Serious renal events</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Interstitial pneumonitis</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Radiation pneumonitis</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Radiation recall</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Sepsis</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Bullous skin reaction including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Cardiovascular events</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>Appropriate wording in the SmPC</td>
<td>N/A</td>
</tr>
<tr>
<td>Hearing loss/hypoacusis</td>
<td>Routine pharmacovigilance activities</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**2.9. PSUR submission**

At the time of granting the marketing authorisation, the submission of periodic safety update reports is not required for this medicinal product. However, the marketing authorisation holder shall submit periodic safety update reports for this medicinal product if the product is included in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83 and published on the European medicines web-portal.

**2.10. Product information**

**2.10.1. User consultation**

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons:
Pemetrexed Lilly is a generic product of the centrally approved medicinal product Alimta (EU/1/04/290/001-002) of the same marketing authorisation holder (Eli Lilly Nederland B.V).

The proposed product information (PI) for Pemetrexed Lilly is almost identical to the PI of the reference product. There are minor differences due to the adaptation of the PL to the last version of the QRD template. However, these changes do not affect the results of the previous readability test, therefore the bridging statement to the Alimta PI is considered acceptable.

3. Benefit-risk balance

This application concerns a generic version of pemetrexed powder for concentrate for solution for infusion. The reference product Alimta is indicated for

Malignant pleural mesothelioma

Alimta in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma.

Non-small cell lung cancer

Alimta in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

No nonclinical studies have been provided for this application but an adequate summary of the available nonclinical information for the active substance was presented and considered sufficient. From a clinical perspective, this application does not contain new data on the pharmacokinetics and pharmacodynamics as well as the efficacy and safety of the active substance. However, the applicant provided a clinical overview on these clinical aspects based on information from published literature which was considered sufficient.

Bioequivalence testing with the reference product is not required under the provisions of the Guideline on the investigation of Bioequivalence (CPMP/EWP/QWP/1401/98/Rev.1) since the product is to be administered as an aqueous intravenous solution containing the same active substance in the same concentration as the currently authorised product.

A benefit/risk ratio comparable to the reference product Alimta can therefore be concluded.

The CHMP, having considered the data submitted in the application and available on the chosen reference medicinal product, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

4. Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Pemetrexed Lilly in the following indications:
**Malignant pleural mesothelioma**

Pemetrexed Lilly in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.

**Non-small cell lung cancer**

Pemetrexed Lilly in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Pemetrexed Lilly is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Pemetrexed Lilly is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

is favourable and therefore recommends the granting of the marketing authorisation subject to the following conditions:

**Conditions or restrictions regarding supply and use**

Medicinal product subject to medical prescription (See Annex I: Summary of Product Characteristics, section 4.2).

**Conditions and requirements of the Marketing Authorisation**

- **Periodic Safety Update Reports**
  
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

- **Risk Management Plan (RMP)**
  
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

  An updated RMP should be submitted:
  
  - At the request of the European Medicines Agency;
  
  - Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

  If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

- **Additional risk minimisation measures**
  
  Not applicable.

- **Obligation to conduct post-authorisation measures**
  
  Not applicable.